| Advanced breast cancer
Ibrance vs Kisqali
Side-by-side clinical, coverage, and cost comparison for advanced breast cancer.Deep comparison between: Ibrance vs Kisqali with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKisqali has a higher rate of injection site reactions vs Ibrance based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kisqali but not Ibrance, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ibrance
Kisqali
At A Glance
Oral
Once daily (21/28-day cycle)
CDK4/6 inhibitor
Oral
Once daily (21/28-day cycle)
CDK4/6 inhibitor
Indications
- Advanced breast cancer
- Malignant neoplasm of breast
- Advanced breast cancer
Dosing
Advanced breast cancer 125 mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a 28-day cycle; dose reductions to 100 mg/day then 75 mg/day available based on tolerability; reduce to 75 mg/day if co-administered with a strong CYP3A inhibitor; 75 mg/day for severe hepatic impairment (Child-Pugh class C).
Malignant neoplasm of breast 400 mg (two 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with an aromatase inhibitor, for 3 years or until disease recurrence or unacceptable toxicity.
Advanced breast cancer 600 mg (three 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with fulvestrant or an aromatase inhibitor.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, dysgeuria
Serious neutropenia, leukopenia, infections, anemia, ILD/pneumonitis
Postmarketing interstitial lung disease/non-infectious pneumonitis, palmar-plantar erythrodysesthesia syndrome
Most common (>=20%) Neutrophils decreased, leukocytes decreased, lymphocytes decreased, hemoglobin decreased, ALT increased, AST increased, infections, nausea, fatigue, headache, creatinine increased, platelets decreased, diarrhea, vomiting, alopecia, cough, rash, back pain
Serious Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions (SJS, TEN), QT interval prolongation, hepatotoxicity, neutropenia
Postmarketing Interstitial lung disease/pneumonitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/DRESS
Pharmacology
Palbociclib is an inhibitor of cyclin-dependent kinases CDK4 and CDK6, which are downstream of signaling pathways driving cellular proliferation; it blocks G1-to-S phase progression in ER-positive breast cancer cells, reducing Rb phosphorylation and E2F expression and signaling, leading to growth arrest.
Ribociclib is a CDK4/6 inhibitor that blocks cyclin D-CDK4/6-mediated phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle in the G1 phase and reducing proliferation in breast cancer models; in combination with antiestrogen therapy (letrozole or fulvestrant), it produces greater tumor growth inhibition than either agent alone.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ibrance
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Kisqali
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Ibrance
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (5/8)
Kisqali
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Ibrance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Kisqali
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Novartis Oncology Universal Co-pay Program: KisqaliCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IbranceView full Ibrance profile
KisqaliView full Kisqali profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.